DK0585705T3 - Anvendelse af monoklone anti-TNF-antistoffer til behandling af bakteriel meningitis - Google Patents
Anvendelse af monoklone anti-TNF-antistoffer til behandling af bakteriel meningitisInfo
- Publication number
- DK0585705T3 DK0585705T3 DK93113072T DK93113072T DK0585705T3 DK 0585705 T3 DK0585705 T3 DK 0585705T3 DK 93113072 T DK93113072 T DK 93113072T DK 93113072 T DK93113072 T DK 93113072T DK 0585705 T3 DK0585705 T3 DK 0585705T3
- Authority
- DK
- Denmark
- Prior art keywords
- bacterial meningitis
- monoclonal anti
- tnf antibodies
- treat bacterial
- bacterial
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93793992A | 1992-08-28 | 1992-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0585705T3 true DK0585705T3 (da) | 1999-07-26 |
Family
ID=25470604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93113072T DK0585705T3 (da) | 1992-08-28 | 1993-08-16 | Anvendelse af monoklone anti-TNF-antistoffer til behandling af bakteriel meningitis |
Country Status (6)
Country | Link |
---|---|
US (1) | US5616321A (fr) |
EP (1) | EP0585705B1 (fr) |
AT (1) | ATE172880T1 (fr) |
DE (1) | DE69321909T2 (fr) |
DK (1) | DK0585705T3 (fr) |
ES (1) | ES2121907T3 (fr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
DE122009000074I1 (de) † | 1993-03-05 | 2011-12-01 | Bayer Healthcare Ag | Humane monoklonale anti-TNF alpha Antikorper. |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
CA2385745C (fr) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methodes pour administrer des anticorps anti-tnf.alpha. |
TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
EP3299393A1 (fr) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Anticorps à domaine unique dirigés contre le facteur alpha de la nécrose tumorale et leurs utilisations |
US7285269B2 (en) * | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
US7101978B2 (en) * | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
JP4484664B2 (ja) * | 2003-11-27 | 2010-06-16 | キヤノン株式会社 | 記録ヘッドカートリッジ |
US7435799B2 (en) * | 2004-01-08 | 2008-10-14 | Applied Molecular Evolution | TNF-α binding molecules |
TWI439284B (zh) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療TNFα相關失調症之多重可變劑量療法 |
CA2898009C (fr) | 2005-05-16 | 2018-03-27 | Rebecca S. Hoffman | Utilisation d'un inhibiteur du tnf alpha pour le traitement de la polyarthrite erosive |
DK1888640T3 (da) | 2005-05-18 | 2012-06-18 | Ablynx Nv | Forbedrede nanobodies mod tumornekrosefaktor-alfa |
NZ571479A (en) | 2006-04-05 | 2012-10-26 | Abbott Biotech Ltd | Antibody purification |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
EP2702077A2 (fr) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante |
CN103764824B (zh) | 2011-06-20 | 2018-04-24 | 西奈山医学院 | 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法 |
US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158273A1 (fr) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Procédés de modulation de la distribution de variant de lysine c-terminal |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
AU2014215639B2 (en) | 2013-01-25 | 2017-03-23 | Thymon, Llc | Compositions for selective reduction of circulating bioactive soluble TNF and methods for treating TNF-mediated disease |
WO2014143205A1 (fr) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Anticorps humains qui se lient au tnf-alpha et leurs procédés de préparation |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
EP2803365A1 (fr) | 2013-05-14 | 2014-11-19 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Utilisation de poclonazépam en combinaison avec un antibiotique dans le traitement de la méningite induite par des bactéries |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
WO2015073884A2 (fr) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Compositions de protéines de liaison génétiquement glycomodifiées |
WO2016160976A2 (fr) | 2015-03-30 | 2016-10-06 | Abbvie Inc. | Protéines de liaison au tnf monovalentes |
EP3078675A1 (fr) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Régime de dosage à induction pour le traitement des maladies liées au tnf alpha |
US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
JOP20190162A1 (ar) | 2016-12-30 | 2019-06-27 | Biocad Joint Stock Co | تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL73883A (en) * | 1984-12-20 | 1990-12-23 | Yeda Res & Dev | Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha |
DE3631229A1 (de) * | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US5075236A (en) * | 1987-04-24 | 1991-12-24 | Teijin Limited | Method of detecting kawasaki disease using anti-tumor necrosis antibody |
GB8806339D0 (en) * | 1988-03-17 | 1988-04-13 | Hoffmann La Roche | Monoclonal antibodies |
NZ229922A (en) * | 1988-07-18 | 1992-04-28 | Chiron Corp | Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions |
WO1990001950A1 (fr) * | 1988-08-19 | 1990-03-08 | Celltech Limited | Produits pharmaceutiques pour therapie anti-neoplastique |
US5360716A (en) * | 1988-10-24 | 1994-11-01 | Otsuka Pharmaceutical Co., Ltd. | Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α |
GB8905400D0 (en) * | 1989-03-09 | 1989-04-19 | Jonker Margreet | Medicaments |
GB8921123D0 (en) * | 1989-09-19 | 1989-11-08 | Millar Ann B | Treatment of ards |
EP0608212A1 (fr) * | 1990-08-27 | 1994-08-03 | Peptide Technology Ltd | Procede de traitement des infections virales |
GB9028123D0 (en) * | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
DE69231828T3 (de) * | 1991-03-18 | 2008-06-19 | New York University | Spezifisch gegen menschlichen Tumornekrosefaktor gerichtete monoklonale und chimäre Antikörper |
WO1994008619A1 (fr) * | 1992-10-08 | 1994-04-28 | The Kennedy Institute Of Rheumatology | Traitement d'affections auto-immunes et inflammatoires |
GB9225448D0 (en) * | 1992-12-04 | 1993-01-27 | Erba Carlo Spa | Improved synthesis of polymer bioactive conjugates |
WO1995015179A1 (fr) * | 1993-12-01 | 1995-06-08 | Unisearch Limited | Procede pour traiter des troubles intestinaux |
-
1993
- 1993-08-16 AT AT93113072T patent/ATE172880T1/de active
- 1993-08-16 DE DE69321909T patent/DE69321909T2/de not_active Expired - Lifetime
- 1993-08-16 ES ES93113072T patent/ES2121907T3/es not_active Expired - Lifetime
- 1993-08-16 EP EP93113072A patent/EP0585705B1/fr not_active Expired - Lifetime
- 1993-08-16 DK DK93113072T patent/DK0585705T3/da active
-
1995
- 1995-03-23 US US08/410,006 patent/US5616321A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0585705A1 (fr) | 1994-03-09 |
US5616321A (en) | 1997-04-01 |
ATE172880T1 (de) | 1998-11-15 |
ES2121907T3 (es) | 1998-12-16 |
DE69321909D1 (de) | 1998-12-10 |
EP0585705B1 (fr) | 1998-11-04 |
DE69321909T2 (de) | 1999-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0585705T3 (da) | Anvendelse af monoklone anti-TNF-antistoffer til behandling af bakteriel meningitis | |
AU4688589A (en) | A method for treatment of endotoxic shock in a mammal | |
GB9115364D0 (en) | Antibody | |
DE69833942D1 (de) | Verwendung einer neurotoxintherapie zur behandlung von prostata erkrankungen | |
DE69221501T2 (de) | Verfahren zum vermindern von durch medizinische vorrichtungen bedingten infektionen | |
ES2084338T3 (es) | Anticuerpos recombinantes especificos para el tnf alfa. | |
GR3026750T3 (en) | Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein. | |
ATA29495A (de) | Zusammensetzung und verfahren zur prävention und behandlung von entzündungen mit immunglobulin a | |
DE68921979T2 (de) | Antikörper für die antilymphozyten-antikörpertherapie. | |
DE69534601D1 (de) | Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien | |
LV11987A (lv) | Aptaukosanas noversanas vai arstesanas metode | |
NO934655L (no) | Legemiddel for gram-positive sykdommer i akvatiske arter | |
DE3773059D1 (de) | Ester von salsalat mit guajakol zur behandlung von phlogistischen bronchopneumopathien. | |
ATE222927T1 (de) | Monoklonaler antikörper gegen den tumorzytotoxischen faktor ii (tcf-ii) | |
NO973659L (no) | Anvendelse av LCK SH2-spesifikke forbindelser til behandling av autoimmune sykdommer og transplantatavvisning | |
DE59008759D1 (de) | Verwendung von interleukin-2 zur behandlung der endotoxinämie. | |
DE69001240T2 (de) | Methoden zur verwendung von 2-isopropyl-2-phenylaminovaleriansaeurenitrilen als immunosupressoren und vasodilatoren. | |
EA200101271A1 (ru) | Блокирующее моноклональное антитело к vla-1 и его применение для лечения воспалительных заболеваний | |
GB2233559A (en) | Antibodies for use in antilymphocyte antibody therapy | |
TR199700791T1 (xx) | Kendiliğinden bağışıklığı olan hastalıkların ve allograft rejeksiyonun tedavisi için LCK SH2 spesifik bileşimlerinin kullanılması. |